Skip to main content
PMC home page
Redox Report : Communications in Free Radical Research logoLink to Redox Report : Communications in Free Radical Research
. 2013 Jul 19;15(2):50–63. doi: 10.1179/174329210X12650506623401

Nox isoforms in vascular pathophysiology: insights from transgenic and knockout mouse models

Jennifer Rivera 1, Christopher G Sobey 2, Anna K Walduck 3, Grant R Drummond 4
PMCID: PMC7067321  PMID: 20500986

Abstract

Elevated reactive oxygen species (ROS) formation in the vascular wall is a key feature of cardiovascular diseases and a likely contributor to oxidative stress, endothelial dysfunction and vascular inflammation. The NADPH oxidases are a family of ROS generating enzymes, of which four members (Nox1, Nox2, Nox4 and Nox5) are expressed in blood vessels. Numerous studies have demonstrated that expression and activity of at least two isoforms of NADPH oxidase – Nox1 and Nox2 – are up-regulated in animal models of hypertension, diabetes and atherosclerosis. However, these observations are merely suggestive of a role for NADPH oxidases in vessel pathology and by no means establish cause and effect. Furthermore, questions surrounding the specificity of current pharmacological inhibitors of NADPH oxidase mean that findings obtained with these compounds must be viewed with caution. Here, we review the literature on studies utilising genetically-modified mouse strains to investigate the roles of NADPH oxidases in experimental models of vascular disease. While several studies on transgenic over-expressing or knockout mice support roles for Nox1- and/or Nox2-containing oxidases as sources of excessive vascular ROS production and causes of endothelial dysfunction in hypertension, atherosclerosis and diabetes, there are still no published reports on the effects of genetic modification of Nox4 or Nox5 in vascular or indeed any other contexts. Further understanding of the roles of specific isoforms of NADPH oxidase in vascular (patho)physiology should provide direction for future programs aimed at developing selective inhibitors of these enzymes as novel therapeutics in cardiovascular disease.

Keywords: NOXI SOFORMS, VASCULAR PATHOPHYSIOLOGY, MOUSE MODELS, ROS

Full Text

The Full Text of this article is available as a PDF (764.5 KB).

References

  • 1.Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245–313. [DOI] [PubMed] [Google Scholar]
  • 2.Selemidis S, Sobey CG, Wingler K, Schmidt HH, Drummond GR. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 2008; 120: 254–291. [DOI] [PubMed] [Google Scholar]
  • 3.Thomas SR, Witting PK, Drummond GR. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2008; 10: 1713–1765. [DOI] [PubMed] [Google Scholar]
  • 4.Bengtsson SH, Gulluyan LM, Dusting GJ, Drummond GR. Novel isoforms of NADPH oxidase in vascular physiology and pathophysiology. Clin Exp Pharmacol Physiol 2003; 30: 849–854. [DOI] [PubMed] [Google Scholar]
  • 5.Malle E, Marsche G, Arnhold J, Davies MJ. Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim Biophys Acta 2006; 1761: 392–415. [DOI] [PubMed] [Google Scholar]
  • 6.Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840–844. [DOI] [PubMed] [Google Scholar]
  • 7.Lassegue B, Clempus RE. NADPH Vascular. oxidases: specific features, expression, and regulation Am J Physiol 2003; 285: R277—R297. [DOI] [PubMed] [Google Scholar]
  • 8.Babior BM, Lambeth JD, Nauseef W The neutrophil NADPH oxidase. Arch Biochem Biophys 2002; 397: 342–344. [DOI] [PubMed] [Google Scholar]
  • 9.Babior BM, Kipnes RS, Curnutte JT. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest 1973; 52: 741–744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Rossi F, Zatti M. Biochemical aspects of phagocytosis in polymorphonuclear leucocytes. NADH and NADPH oxidation by the granules of resting and phagocytizing cells. Experientia 1964; 20: 21–23. [DOI] [PubMed] [Google Scholar]
  • 11.Kawahara T, Ritsick D, Cheng G, Lambeth JD. Point mutations in the proline-rich region of p22phox are dominant inhibitors of Noxl-and Nox2-dependent reactive oxygen generation. J Biol Chem 2005; 280: 31859–31869. [DOI] [PubMed] [Google Scholar]
  • 12.Hordijk PL. Regulation of NADPH oxidases: the role of Rac proteins. Circ Res 2006; 98: 453–462. [DOI] [PubMed] [Google Scholar]
  • 13.Bokoch GM, Zhao T. Regulation of the phagocyte NADPH oxidase by Rac GTPase. Antioxid Redox Signal 2006; 8: 1533–1548. [DOI] [PubMed] [Google Scholar]
  • 14.Van Buul JD, Fernandez-Borja M, Anthony EC, Hordijk PL. Expression and localization of NOX2 and NOX4 in primary human endothelial cells. Antioxid Redox Signal 2005; 7: 308–317. [DOI] [PubMed] [Google Scholar]
  • 15.Li JM, Shah AM. Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem 2002; 277: 19952–19960. [DOI] [PubMed] [Google Scholar]
  • 16.Chamseddine AH, Miller FJ Jr. Gp9 lphox contributes to NADPH oxidase activity in aortic fibroblasts but not smooth muscle cells. Am J Physiol 2003; 285: H2284–H2289. [DOI] [PubMed] [Google Scholar]
  • 17.Touyz RM, Chen X, Tabet F et al. Expression of a functionally active gp9 lphox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 2002; 90: 1205–1213. [DOI] [PubMed] [Google Scholar]
  • 18.Lassegue B, Sorescu D, Szocs K et al. Novel gp91(phox) homologues in vascular smooth muscle cells: Noxl mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 2001; 88: 888–894. [DOI] [PubMed] [Google Scholar]
  • 19.Kalinina N, Agrotis A, Tararak E et al. Cytochrome b558-dependent NAD(P)H oxidase-phox units in smooth muscle and macrophages of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2002; 22: 2037–2043. [DOI] [PubMed] [Google Scholar]
  • 20.Suh YA, Arnold RS, Lassegue B et al. Cell transformation by the superoxide-generating oxidase Moxl. Nature 1999; 401: 79–82. [DOI] [PubMed] [Google Scholar]
  • 21.Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, Griendling KK. Distinct subcellular localizations of Noxl and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2004; 24: 677–683. [DOI] [PubMed] [Google Scholar]
  • 22.Ago T, Kitazono T, Kuroda J et al. NAD(P)H oxidases in rat basilar arterial endothelial cells. Stroke 2005; 36: 1040–1046. [DOI] [PubMed] [Google Scholar]
  • 23.Banfi B, Clark RA, Steger K, Krause KH. Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. J Biol Chem 2003; 278: 3510–3513. [DOI] [PubMed] [Google Scholar]
  • 24.Hanna IR, Hilenski LL, Dikalova A et al. Functional association of Noxl with p22phox in vascular smooth muscle cells. Free Radic Biol Med 2004; 37: 1542–1549. [DOI] [PubMed] [Google Scholar]
  • 25.Ellmark SH, Dusting GJ, Fui MN, Guzzo-Pemell N, Drummond GR. The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle. Cardiovasc Res 2005; 65: 495–504. [DOI] [PubMed] [Google Scholar]
  • 26.Wingler K, Wunsch S, Kreutz R, Rothermund L, Paul M, Schmidt HH. Upregulation of the vascular NAD(P)H-oxidase isoforms Noxl and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radic Biol Med 2001; 31: 1456–1464. [DOI] [PubMed] [Google Scholar]
  • 27.Katsuyama M, Fan C, Yabe-Nishimura C. NADPH oxidase is involved in prostaglandin F2alpha-induced hypertrophy of vascular smooth muscle cells: induction of NOX1 by PGF2alpha. J Biol Chem 2002; 277: 13438–13442. [DOI] [PubMed] [Google Scholar]
  • 28.Manea A, IrMa Tanase L, Raicu M, Simionescu M. JAK/STAT signaling pathway regulates Noxl and Nox4-based NADPH oxidase in human aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2010; 30: 105–112. [DOI] [PubMed] [Google Scholar]
  • 29.Sorescu GP, Song H, Tressel SL et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a noxl -based NADPH oxidase. Circ Res 2004; 95: 773–779. [DOI] [PubMed] [Google Scholar]
  • 30.Matsuno K, Yamada H, Iwata K et al. Noxl is involved in angiotensin II-mediated hypertension: a study in Noxl -deficient mice. Circulation 2005; 112: 2677–2685. [DOI] [PubMed] [Google Scholar]
  • 31.Wendt MC, Daiber A, Kleschyov AL et al. Differential effects of diabetes on the expression of the gp9lphox homologues noxl and nox4. Free Radic Biol Med 2005; 39: 381–391. [DOI] [PubMed] [Google Scholar]
  • 32.Geiszt M, Kopp JB, Vamai P, Leto TL. Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci USA 2000; 97: 8010–8014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Ago T, Kitazono T, Ooboshi H et al. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 2004; 109: 227–233. [DOI] [PubMed] [Google Scholar]
  • 34.Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal 2006; 18: 69–82. [DOI] [PubMed] [Google Scholar]
  • 35.Ambasta RK, Kumar P, Griendling KK, Schmidt HH, Busse R, Brandes RP. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem 2004; 279: 45935–45941. [DOI] [PubMed] [Google Scholar]
  • 36.Moe KT, Aulia S, Jiang F et al. Differential upregulation of Nox homologues of NADPH oxidase by tumor necrosis factor-alpha in human aortic smooth muscle and embryonic kidney cells. J Cell Mol Med 2006; 10: 231–239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Park HS, Chun JN, Jung HY, Choi C, Bae YS. Role of NADPH oxidase 4 in lipopolysaccharide-induced proinflammatory responses by human aortic endothelial cells. Cardiovasc Res 2006; 72: 447–455. [DOI] [PubMed] [Google Scholar]
  • 38.Banfi B, Molnar G, Maturana A et al. A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes. J Biol Chem 2001; 276: 37594–37601. [DOI] [PubMed] [Google Scholar]
  • 39.BelAiba RS, Djordjevic T, Petry A et al. NOX5 variants are functionally active in endothelial cells. Free Radic Biol Med 2007; 42: 446–459. [DOI] [PubMed] [Google Scholar]
  • 40.Jay DB, Papaharalambus CA, Seidel-Rogol B, Dikalova AE, Lassegue B, Griendling KK. Nox5 mediates PDGF-induced proliferation in human aortic smooth muscle cells. Free Radic Biol Med 2008; 45: 329–335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Guzik TJ, Chen W, Gongora MC et al. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol 2008; 52: 1803–1809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol 1994; 11: 95–102. [DOI] [PubMed] [Google Scholar]
  • 43.Gavazzi G, Banfi B, Deffert C et al. Decreased blood pressure in NOX1-deficient mice. FEBS Lett 2006; 580: 497–504. [DOI] [PubMed] [Google Scholar]
  • 44.Dikalova A, Clempus R, Lassegue B et al. Noxl overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005; 112: 2668–2676. [DOI] [PubMed] [Google Scholar]
  • 45.Yogi A, Mercure C, Touyz J et al. Renal redox-sensitive signaling, but not blood pressure, is attenuated by Noxl knockout in angiotensin II-dependent chronic hypertension. Hypertension 2008; 51: 500–506. [DOI] [PubMed] [Google Scholar]
  • 46.Wang HD, Xu S, Johns DG et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 2001; 88: 947–953. [DOI] [PubMed] [Google Scholar]
  • 47.Jung O, Schreiber JG, Geiger H, Pedrazzini T, Busse R, Brandes RP. gp9lphox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 2004; 109: 1795–1801. [DOI] [PubMed] [Google Scholar]
  • 48.Touyz RM, Mercure C, He Y et al. Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp9lphox-containing NADPH oxidase. Hypertension 2005; 45: 530–537. [DOI] [PubMed] [Google Scholar]
  • 49.Carlstrom M, Lai EY, Ma Z, Patzak A, Brown RD, Persson AE. Role of NOX2 in the regulation of afferent arteriole responsiveness. Am J Physiol 2009; 296: R72–R79. [DOI] [PubMed] [Google Scholar]
  • 50.Bendall JK, Rinze R, Adlam D et al. Endothelial Nox2 overexpression potentiates vascular oxidative stress and hemodynamic response to angiotensin II: studies in endothelial-targeted Nox2 transgenic mice. Circ Res 2007; 100: 1016–1025. [DOI] [PubMed] [Google Scholar]
  • 51.Landmesser U, Cai H, Dikalov S et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002; 40: 511–515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Guzik TJ, Hoch NE, Brown KA et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204: 2449–2460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Landmesser U, Dikalov S, Price SR et al.Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J C1M Invest 2003; 111: 1201–1209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Miriyala S, Gongora Nieto MC, Mingone C et al. Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation 2006; 113: 2818–2825. [DOI] [PubMed] [Google Scholar]
  • 55.Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol 2004; 24: 1006–1014. [DOI] [PubMed] [Google Scholar]
  • 56.Plump AS, Smith JD, Hayek T et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343–353. [DOI] [PubMed] [Google Scholar]
  • 57.Barry-Lane PA, Patterson C, van der Merwe M et al. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest 2001; 108: 1513–1522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Hsich E, Segal BH, Pagano PJ et al. Vascular effects following homozygous disruption of p47(phox) : An essential component of NADPH oxidase. Circulation 2000; 101: 1234–1236. [DOI] [PubMed] [Google Scholar]
  • 59.Vendrov AE, Hakim ZS, Madamanchi NR, Rojas M, Madamanchi C, Runge MS. Atherosclerosis is attenuated by limiting superoxide generation in both macrophages and vessel wall cells. Arterioscler Thromb Vasc Biol 2007; 27: 2714–2721. [DOI] [PubMed] [Google Scholar]
  • 60.Judkins CP, Diep H, Broughton BR et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE' mice. Am J Physiol 2010; 298: H24–H32. [DOI] [PubMed] [Google Scholar]
  • 61.Kirk EA, Dinauer MC, Rosen H, Chait A, Heinecke JW, LeBoeuf RC. Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2000; 20: 1529–1535. [DOI] [PubMed] [Google Scholar]
  • 62.Sheehan AL, Takapoo M, Banfi B, Miller FJ Jr. Role for Noxl NADPH oxidase in atherosclerosis. Circulation 2007; 116: II_244-c-. [Google Scholar]
  • 63.Hui DY. Intimal hyperplasia in murine models. Curr Drug Targets 2008; 9: 251–260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Szocs K, Lassegue B, Sorescu D et al. Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol 2002; 22: 21–27. [DOI] [PubMed] [Google Scholar]
  • 65.Lee MY, San Martin A, Mehta PK et al. Mechanisms of vascular smooth muscle NADPH oxidase 1 (Noxl) contribution to injury-induced neointimal formation. Arterioscler Thromb Vasc Biol 2009; 29: 480–487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Niu XL, Madamanchi NR, Vendrov AE et al. Nox activator 1: a potential target for modulation of vascular reactive oxygen species in atherosclerotic arteries. Circulation 2010; 121: 549–559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Chen Z, Keaney JF Jr, Schulz E et al. Decreased neointimal formation in Nox2-deficient mice reveals a direct role for NADPH oxidase in the response to arterial injury. Proc Natl Acad Sci USA 2004; 101: 13014–13019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Chen H, Song YS, Chan PH. Inhibition of NADPH oxidase is neuroprotective after ischemia-reperfusion. J Cereb Blood Flow Metab 2009; 29: 1262–1272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Kahles T, Luedike P, Endres M et al. NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke 2007; 38: 3000–3006. [DOI] [PubMed] [Google Scholar]
  • 70.Kunz A, Anrather J, Zhou P, Orio M, Iadecola C. Cyclooxygenase-2 does not contribute to postischemic production of reactive oxygen species. J Cereb Blood Flow Metab 2007; 27: 545–551. [DOI] [PubMed] [Google Scholar]
  • 71.Walder CE, Green SP, Darbonne WC et al. Ischemic stroke injury is reduced in mice lacking a functional NADPH oxidase. Stroke 1997; 28: 2252–2258. [DOI] [PubMed] [Google Scholar]
  • 72.Jackman KA, Miller AA, De Silva TM, Crack PJ, Drummond GR, Sobey CG. Reduction of cerebral infarct volume by apocynin requires pretreatment and is absent in Nox2-deficient mice. Br J Pharmacol 2009; 156: 680–688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Brait VH, Jackman KA, Walduck AK et al. Mechanisms contributing to cerebral infarct size after stroke: gender, reperfusion, T lymphocytes, and Nox2-derived superoxide J Cereb Blood Flow Metab 2010; Epub ahead of print. [DOI] [PMC free article] [PubMed]
  • 74.Jackman KA, Miller AA, Drummond GR, Sobey CG. Importance of NOX1 for angiotensin II-induced cerebrovascular superoxide production and cortical infarct volume following ischemic stroke. Brain Res 2009; 1286: 215–220. [DOI] [PubMed] [Google Scholar]
  • 75.Huang CK, Than L, Hannigan MO, Ai Y, Leto TL. P47(phox)-deficient NADPH oxidase defect in neutrophils of diabetic mouse strains, C57BL/6J-m db/db and db/+. J Leukoc Biol 2000; 67: 210–215. [DOI] [PubMed] [Google Scholar]
  • 76.Hummel KP, Coleman DL, Lane PW. The influence of genetic background on expression of mutations at the diabetes locus in the mouse. I. C57BL-KsJ and C57BL-6J strains. Biochem Genet 1972; 7: 1–13. [DOI] [PubMed] [Google Scholar]
  • 77.Heyworth PG, Cross AR, Cumutte JT. Chronic granulomatous disease. Curr Opin Immunol 2003; 15: 578–584. [DOI] [PubMed] [Google Scholar]
  • 78.Violi F, Sanguigni V, Carnevale R et al. Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation 2009; 120: 1616–1622. [DOI] [PubMed] [Google Scholar]

Articles from Redox Report : Communications in Free Radical Research are provided here courtesy of Taylor & Francis

RESOURCES